Skip to main content
. 2019 Feb 9;3(2):e175. doi: 10.1097/HS9.0000000000000175

Figure 3.

Figure 3

Progression-free survival with obinutuzumab-chlorambucil versus rituximab-chlorambucil in the CLL11 study. G-Clb = obinutuzumab-chlorambucil, R-Clb = rituximab-chlorambucil. Reprinted from Goede et al36 with permission from the Massachusetts Medical Society.